Imagion Biosystems Limited Logo

Imagion Biosystems Limited

IBXXF

(0.5)
Stock Price

0,04 USD

-188.22% ROA

282.94% ROE

-0.2x PER

Market Cap.

1.851.143,09 USD

-159.41% DER

0% Yield

-186.62% NPM

Imagion Biosystems Limited Stock Analysis

Imagion Biosystems Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Imagion Biosystems Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a reasonable amount of debt compared to its ownership (98%), suggesting a balanced financial position and a moderate level of risk.

2 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

3 ROE

Negative ROE (-109.07%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-98.31%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's elevated P/BV ratio (8.84x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Imagion Biosystems Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Imagion Biosystems Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Imagion Biosystems Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Imagion Biosystems Limited Revenue
Year Revenue Growth
2014 6.110
2015 5.493 -11.25%
2016 12 -45666.67%
2017 20.102 99.94%
2018 191.477 89.5%
2019 410.854 53.4%
2020 205.717 -99.72%
2021 232.865 11.66%
2022 473.429 50.81%
2023 8.561.488 94.47%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Imagion Biosystems Limited Research and Development Expenses
Year Research and Development Expenses Growth
2014 2.238.795
2015 3.884.641 42.37%
2016 6.024.840 35.52%
2017 2.155.714 -179.48%
2018 3.295.676 34.59%
2019 2.269.006 -45.25%
2020 2.860.772 20.69%
2021 2.704.032 -5.8%
2022 3.615.851 25.22%
2023 6.084.560 40.57%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Imagion Biosystems Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 86.765
2015 245.793 64.7%
2016 514.320 52.21%
2017 2.724.463 81.12%
2018 3.965.413 31.29%
2019 1.816.810 -118.26%
2020 2.823.315 35.65%
2021 3.759.268 24.9%
2022 5.516.565 31.85%
2023 3.504.472 -57.42%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Imagion Biosystems Limited EBITDA
Year EBITDA Growth
2014 -2.271.790
2015 -3.969.776 42.77%
2016 -6.539.148 39.29%
2017 -6.652.503 1.7%
2018 -8.118.469 18.06%
2019 -3.281.360 -147.41%
2020 -4.996.968 34.33%
2021 -5.615.967 11.02%
2022 -8.697.040 35.43%
2023 -7.843.328 -10.88%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Imagion Biosystems Limited Gross Profit
Year Gross Profit Growth
2014 6.110
2015 5.493 -11.25%
2016 12 -45666.67%
2017 20.102 99.94%
2018 -3.104.199 100.65%
2019 -1.858.152 -67.06%
2020 -2.655.055 30.01%
2021 -2.471.167 -7.44%
2022 -3.142.422 21.36%
2023 2.476.928 226.87%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Imagion Biosystems Limited Net Profit
Year Net Profit Growth
2014 -2.514.978
2015 -4.400.945 42.85%
2016 -12.413.724 64.55%
2017 -7.794.602 -59.26%
2018 -8.340.013 6.54%
2019 -3.432.506 -142.97%
2020 -5.364.007 36.01%
2021 -6.024.706 10.97%
2022 -9.807.208 38.57%
2023 -9.581.680 -2.35%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Imagion Biosystems Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 -123
2015 -215 42.99%
2016 -5 -5250%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Imagion Biosystems Limited Free Cashflow
Year Free Cashflow Growth
2014 -2.474.651
2015 -4.580.828 45.98%
2016 -3.207.072 -42.84%
2017 -7.346.991 56.35%
2018 -6.650.775 -10.47%
2019 -4.194.398 -58.56%
2020 -4.630.950 9.43%
2021 -5.287.324 12.41%
2022 -8.581.529 38.39%
2023 -1.231.625 -596.76%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Imagion Biosystems Limited Operating Cashflow
Year Operating Cashflow Growth
2014 -2.430.657
2015 -4.223.809 42.45%
2016 -3.207.072 -31.7%
2017 -6.977.385 54.04%
2018 -6.567.210 -6.25%
2019 -4.182.045 -57.03%
2020 -4.623.090 9.54%
2021 -5.068.491 8.79%
2022 -8.074.214 37.23%
2023 -1.148.199 -603.21%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Imagion Biosystems Limited Capital Expenditure
Year Capital Expenditure Growth
2014 43.994
2015 357.019 87.68%
2016 0 0%
2017 369.606 100%
2018 83.565 -342.3%
2019 12.353 -576.48%
2020 7.860 -57.16%
2021 218.833 96.41%
2022 507.315 56.86%
2023 83.426 -508.1%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Imagion Biosystems Limited Equity
Year Equity Growth
2014 -3.971.662
2015 -8.863.683 55.19%
2016 11.689.649 175.83%
2017 6.952.556 -68.13%
2018 3.869.228 -79.69%
2019 2.973.517 -30.12%
2020 12.913.867 76.97%
2021 13.305.279 2.94%
2022 4.677.496 -184.45%
2023 -3.788.047 223.48%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Imagion Biosystems Limited Assets
Year Assets Growth
2014 338.507
2015 788.188 57.05%
2016 12.141.642 93.51%
2017 7.641.326 -58.89%
2018 5.187.459 -47.3%
2019 4.872.097 -6.47%
2020 14.119.004 65.49%
2021 14.115.155 -0.03%
2022 9.975.622 -41.5%
2023 4.586.272 -117.51%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Imagion Biosystems Limited Liabilities
Year Liabilities Growth
2014 4.310.170
2015 9.651.871 55.34%
2016 451.993 -2035.4%
2017 688.770 34.38%
2018 1.318.231 47.75%
2019 1.898.580 30.57%
2020 1.205.137 -57.54%
2021 809.876 -48.81%
2022 5.298.126 84.71%
2023 8.374.319 36.73%

Imagion Biosystems Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.14
Net Income per Share
-0.26
Price to Earning Ratio
-0.2x
Price To Sales Ratio
0.4x
POCF Ratio
-0.32
PFCF Ratio
-0.34
Price to Book Ratio
-0.45
EV to Sales
1.66
EV Over EBITDA
-1.06
EV to Operating CashFlow
-1.44
EV to FreeCashFlow
-1.4
Earnings Yield
-5.08
FreeCashFlow Yield
-2.96
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.83
Graham NetNet
-0.25

Income Statement Metrics

Net Income per Share
-0.26
Income Quality
0.61
ROE
2.83
Return On Assets
-1.88
Return On Capital Employed
15.02
Net Income per EBT
1
EBT Per Ebit
1.06
Ebit per Revenue
-1.76
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0.58
Research & Developement to Revenue
0.9
Stock Based Compensation to Revenue
0.07
Gross Profit Margin
0.1
Operating Profit Margin
-1.76
Pretax Profit Margin
-1.87
Net Profit Margin
-1.87

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.16
Free CashFlow per Share
-0.17
Capex to Operating CashFlow
-0.03
Capex to Revenue
0.04
Capex to Depreciation
0.2
Return on Invested Capital
-3.61
Return on Tangible Assets
-1.88
Days Sales Outstanding
5.81
Days Payables Outstanding
139.98
Days of Inventory on Hand
12.56
Receivables Turnover
62.78
Payables Turnover
2.61
Inventory Turnover
29.07
Capex per Share
0.01

Balance Sheet

Cash per Share
0,01
Book Value per Share
-0,12
Tangible Book Value per Share
-0.12
Shareholders Equity per Share
-0.12
Interest Debt per Share
0.18
Debt to Equity
-1.59
Debt to Assets
1.32
Net Debt to EBITDA
-0.8
Current Ratio
0.12
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-541653
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
71324.5
Debt to Market Cap
3.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Imagion Biosystems Limited Dividends
Year Dividends Growth

Imagion Biosystems Limited Profile

About Imagion Biosystems Limited

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.

CEO
Mr. Robert Romeo Proulx
Employee
0
Address
5601 Oberlin Drive
San Diego, 92121

Imagion Biosystems Limited Executives & BODs

Imagion Biosystems Limited Executives & BODs
# Name Age
1 Ms. Melanie Leydin C.A.
Non-Executive Director & Company Secretary
70
2 Mr. Ward Detwiler
Chief Business Officer
70
3 Mr. Robert Romeo Proulx
Executive Chairman
70

Imagion Biosystems Limited Competitors